Información de Immutep Ltd, dividendo de Immutep Ltd, actividades de los accionistas y más

Más Datos de Immutep Ltd Compañía

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Información de Immutep Ltd



Símbolo de cotizaciónIMMP

Nombre de la empresaImmutep Ltd

Fecha de salida a bolsaJun 23, 1988

Director ejecutivoVoigt (Marc)

Número de empleados- -

Tipo de seguridadDepository Receipt

Fin del año fiscalJun 23

DirecciónLevel 32, Suite 32.07 Australia Square

CiudadSYDNEY

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísAustralia

Código postal2000

Teléfono61283157003

Sitio Webhttps://www.immutep.com/

Símbolo de cotizaciónIMMP

Fecha de salida a bolsaJun 23, 1988

Director ejecutivoVoigt (Marc)

Ejecutivos de Immutep Ltd



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Prof. Frederic Triebel, M.D., Ph.D.

Chief Scientific Officer, Executive Director

17.06K

--

Mr. Marc Voigt

Chief Executive Officer, Executive Director

45.00

--

Ms. Deanne Miller

Chief Operating Officer, General Counsel, Company Secretary

--

Dr. Russell John Howard, Ph.D.

Independent Non-Executive Chairman of the Board

--

Mr. Peter A. (Pete) Meyers

Independent Non-Executive Deputy Chairman of the Board

--

Ms. Indira Naidu

Company Secretary

--

Ms. Lis (Elisabeth) Boyce

Non-Executive Director

--

Dr. Stephan Winckels

Chief Medical Officer

--

Mr. Christian Mueller

Chief Development Officer

--

Ms. Eleanor Pearson

Investors Relation

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Prof. Frederic Triebel, M.D., Ph.D.

Chief Scientific Officer, Executive Director

17.06K

--

Mr. Marc Voigt

Chief Executive Officer, Executive Director

45.00

--

Ms. Deanne Miller

Chief Operating Officer, General Counsel, Company Secretary

--

Dr. Russell John Howard, Ph.D.

Independent Non-Executive Chairman of the Board

--

Mr. Peter A. (Pete) Meyers

Independent Non-Executive Deputy Chairman of the Board

--

Ms. Indira Naidu

Company Secretary

--

Desglose de ingresos

La empresa aún no ha revelado los datos relevantes.

La empresa aún no ha revelado los datos relevantes.

Por negocio

Por región

La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: dom., 1 de feb

Accionistas

Tipos de accionistas

Accionistas

Proporción

Pengana Capital Group Limited

0.66%

BlackRock Institutional Trust Company, N.A.

0.39%

Meridian Wealth Management, LLC

0.31%

Sender Company & Partners, Inc

0.15%

Morgan Stanley & Co. LLC

0.11%

Otro

98.38%

Accionistas

Proporción

Pengana Capital Group Limited

0.66%

BlackRock Institutional Trust Company, N.A.

0.39%

Meridian Wealth Management, LLC

0.31%

Sender Company & Partners, Inc

0.15%

Morgan Stanley & Co. LLC

0.11%

Otro

98.38%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor/Hedge Fund

0.96%

Investment Advisor

0.92%

Research Firm

0.19%

Hedge Fund

0.12%

Venture Capital

0.02%

Individual Investor

0.01%

Otro

97.78%

Participación institucional



Actualizado: jue., 1 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

56

3.30M

2.24%

-356.89K

2025Q3

54

2.86M

1.94%

-666.36K

2025Q2

57

2.80M

1.91%

-1.07M

2025Q1

57

2.80M

1.92%

-1.15M

2024Q4

60

6.95M

4.78%

-4.23M

2024Q3

60

9.14M

6.30%

-2.51M

2024Q2

63

9.65M

6.65%

+2.67M

2024Q1

67

3.50M

2.94%

-1.44M

2023Q4

66

3.16M

2.65%

-1.77M

2023Q3

71

3.00M

2.53%

-4.97M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Pengana Capital Group Limited

970.61K

0.66%

--

May 31, 2025

BlackRock Institutional Trust Company, N.A.

580.44K

0.39%

-19.49K

-3.25%

Sep 30, 2025

Meridian Wealth Management, LLC

420.90K

0.29%

+48.20K

+12.93%

Sep 30, 2025

Sender Company & Partners, Inc

215.86K

0.15%

+93.11K

+75.85%

Sep 30, 2025

Morgan Stanley & Co. LLC

160.47K

0.11%

+47.50K

+42.05%

Sep 30, 2025

AllianceBernstein L.P.

140.05K

0.1%

+60.49K

+76.04%

Jun 30, 2024

Susquehanna International Group, LLP

95.25K

0.06%

+36.94K

+63.36%

Sep 30, 2025

Verition Fund Management LLC

75.00K

0.05%

+31.00K

+70.45%

Sep 30, 2025

UBS Financial Services, Inc.

25.09K

0.02%

-39.75K

-61.30%

Sep 30, 2025

Jane Street Capital, L.L.C.

55.46K

0.04%

+55.46K

--

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

iShares Biotechnology ETF

0.02%

ActivePassive International Equity ETF

0%

DFA Dimensional International Small Cap ETF

0%

iShares Biotechnology ETF

Proporción0.02%

ActivePassive International Equity ETF

Proporción0%

DFA Dimensional International Small Cap ETF

Proporción0%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos